Phase 2 N=36 RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=118 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Tuberous Sclerosis Complex (TSC) · Lymphangioleiomyomatosis (LAM)
Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001
Phase 4 N=40 Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Renal Angiomyolipoma
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 39; 6; 2 Participants
N/A N=14 Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants
Phase 2 N=9 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Phase 2 N=52 Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Kidney Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants
N/A N=10 Renal Retention of Microbubbles
- Study Focus: Renal Retention of Lipid Microbubbles
Primary: Renal Video Intensity Units — 19 units on a scale
N/A N=20 The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Renal Cancer · Tumor, Solid · Kidney Cancer
Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors
N/A N=11 Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Kidney Cancer
Primary: Successful Capture of IO-CEUS Images — 10 participants
N/A N=10 Measurement of Kidney Blood Flow and Oxygen Levels by MRI
Chronic Kidney Disease
Primary: Measurement of Renal Blood Flow of the Kidney by the PAH Method — 190 ml/min
Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Phase 2 N=92 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Carcinoma · Renal Cell · Non Clear Cell Renal Carcinoma
Primary: To Evaluate Efficacy of RAD001 as Monotherapy for the Treatment of Papillary Renal Cancer. Efficacy is Defined as the Percentage of Patients Progression-free at 6…
Phase 2 N=25 Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Chronic Kidney Diseases · Cystic Kidney Disease
Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants
Phase 2 N=73 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Advanced and Metastatic Silent Neuro-Endocrine Tumors · Carcinoma · Neuroendocrine
Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants
N/A N=104 Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones
Urolithiasis · Urinary Lithiasis · Kidney Calculi
Primary: Stone Clearance — 76 participants
Phase 3 N=226 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Renal Cell Carcinoma · Kidney Cancer
Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023
Phase 2 N=25 Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Renal Cancer
Primary: Difference in Median Progression Free Survival Time Between Favorable and Unfavorable Biomarker Group
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 2 N=63 Contrast-enhanced Ultrasound of the Kidney
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
N/A N=108 Trial Assessing Renal Damage During Ureteroscopy
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
Phase 2 N=80 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Kidney Cancer
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
N/A N=618 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
Phase 4 N=28 Renin and Renal Biomarker Response to Angiotensin II
Septic Shock · Acute Kidney Injury
Primary: Change in Plasma Renin Levels — -15; 69; -6; 26 pg/mL
Phase 2 N=15 Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
N/A N=47 Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
N/A N=34 Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants
Phase 3 N=89 Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001